KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Dupilumab Efficacy in Children With Eosinophilic Esophagitis With Prior Swallowed Topical Corticosteroid Use: A Subgroup Analysis.

Mirna Chehade, Salvatore Oliva, Dhandapani Ashok, Ruiqi Liu, Jennifer Maloney, Raolat M Abdulai, Margee Louisias, Allen Radin

Am J Gastroenterol 121(3) 649-660

PMID40531526
PMCIDPMC12947915
DOI10.14309/ajg.0000000000003599
发表日期2025-06-18
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 7 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 1.:非 KM 图;Figure 2.:非 KM 图;Figure 3.:非 KM 图;Figure 4.:非 KM 图;另有 2 张未列出。
摘要

摘要

INTRODUCTION: Swallowed topical corticosteroids (STCs) are commonly used to treat eosinophilic esophagitis (EoE); however, not all patients respond and others may be intolerant or have contraindications. We assessed dupilumab efficacy in children with EoE with prior swallowed topical corticosteroids (STC) use and with prior inadequate response, intolerance, and/or contraindication (IRIC) to STCs in the phase 3 EoE KIDS study. METHODS: Eligible patients were aged 1-11 years with EoE unresponsive to proton-pump inhibitors. In part A, patients were randomized to weight-tiered higher-exposure or lower-exposure dupilumab, or placebo up to week (W)16. In part B, dupilumab groups continued treatment, whereas patients receiving placebo switched to higher-exposure or lower-exposure dupilumab through W52. Efficacy by prior STC status was assessed at W16 and W52. RESULTS: Of 102 patients, 82 (80%) received prior STCs and 59 (58%) had prior IRIC to STCs. At W16, higher-exposure dupilumab improved rates of histologic remission vs placebo in patients with prior STC use (60.7% vs 0.0%, nominal P < 0.0001) and prior IRIC to STCs (60.9% vs 0.0%, nominal P < 0.0001). Secondary endoscopic and histologic outcomes were similar. Responses were maintained at W52 with higher-exposure dupilumab, with improvements observed in patients who switched from placebo to higher-exposure dupilumab. Results were similar or numerically lower with lower-exposure dupilumab. Findings seemed comparable in those without prior STC use or prior IRIC, although patient numbers were small. Dupilumab safety was consistent with the known safety profile. DISCUSSION: Dupilumab may be an effective treatment in children with EoE with prior STC use or prior IRIC to STCs.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(7,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1无图注
非 KM Figure
Figure 1.Proportion of patients in higher-exposure dupilumab or placebo groups achieving PEC ≤6 eos/hpf with or without prior STC use at ( a ) week 16 and ( b ) week 52, and with or without prior IRIC to STCs at ( c ) week 16 and ( d ) week 52. a Patients with missing PEC at week 16 owing to the coronavirus disease 2019 (COVID-19) pandemic were imputed by multiple imputations; patients with missing PEC for any other reason were considered nonresponders. **** P < 0.0001, *** P < 0.001, * P < 0.05 vs placebo. P values are nominal. CI, confidence interval; COVID-19, coronavirus disease 2019; eos/hpf, eosinophils per high-power field; IRIC, inadequate response, intolerance, and/or contraindication; NI, number imputed; PEC, peak esophageal intraepithelial eosinophil count; STC, swallowed topical corticosteroid.
非 KM Figure
Figure 2.Proportion of patients in higher-exposure dupilumab or placebo groups achieving PEC <15 eos/hpf with or without prior STC use at ( a ) week 16 and ( b ) week 52, and with or without prior IRIC to STCs at ( c ) week 16 and ( d ) week 52. a Patients with missing PEC at week 16 owing to the COVID-19 pandemic were imputed by multiple imputations; patients with missing PEC for any other reason were considered nonresponders. **** P < 0.0001, ** P < 0.01 vs placebo. P values are nominal. CI, confidence interval; COVID-19, coronavirus disease 2019; eos/hpf, eosinophils per high-power field; IRIC, inadequate response, intolerance, and/or contraindication; NI, number imputed; PEC, peak esophageal intraepithelial eosinophil count; STC, swallowed topical corticosteroid.
非 KM Figure
Figure 3.Percent change from part A baseline in PEC with higher-exposure dupilumab or placebo in patients with or without prior STC use at ( a ) week 16 and ( b ) week 52, and with or without prior IRIC to STCs at ( c ) week 16 and ( d ) week 52. a Missing values at week 16 owing to the COVID-19 pandemic were imputed by multiple imputations; missing values for any other reason were imputed by the worst observation carried forward method. **** P < 0.0001 vs placebo. P values are nominal. COVID-19, coronavirus disease 2019; IRIC, inadequate response, intolerance, and/or contraindication; LS, least squares; NI, number imputed; PEC, peak esophageal intraepithelial eosinophil count; STC, swallowed topical corticosteroid.
非 KM Figure
Figure 4.Absolute change from part A baseline in EoE-HSS grade (severity) and stage (extent) scores with higher-exposure dupilumab or placebo in patients with or without prior STC use at ( a , e ) week 16 and ( b , f ) week 52, and with or without prior IRIC to STCs at ( c , g ) week 16 and ( d , h ) week 52. a Missing values at week 16 owing to the COVID-19 pandemic were imputed by multiple imputations; missing values for any other reason were imputed by the worst observation carried forward method. **** P < 0.0001, *** P < 0.001 vs placebo. P values are nominal. COVID-19, coronavirus disease 2019; EoE-HSS, Eosinophilic Esophagitis Histologic Scoring System; IRIC, inadequate response, intolerance, and/or contraindication; LS, least squares; NI, number imputed; STC, swallowed topical corticosteroid.
非 KM Figure
Figure 5.Absolute change from part A tbaseline in EoE-EREFS total score with higher-exposure dupilumab or placebo in patients with or without prior STC use at ( a ) week 16 and ( b ) week 52, and with or without prior IRIC to STCs at ( c ) week 16 and ( d ) week 52. a Missing values at week 16 owing to the COVID-19 pandemic were imputed by multiple imputations; missing values for any other reason were imputed by the worst observation carried forward method. **** P < 0.0001, ** P < 0.01 vs placebo. P values are nominal. COVID-19, coronavirus disease 2019; EoE-EREFS, Eosinophilic Esophagitis Endoscopic Reference Score; IRIC, inadequate response, intolerance, and/or contraindication; LS, least squares; NI, number imputed; STC, swallowed topical corticosteroid.
非 KM Figure
Figure 6.Absolute change from part A baseline in proportion of days with 1 or more EoE sign(s) as measured by the PESQ-C with higher-exposure dupilumab or placebo, in patients with or without prior STC use at ( a ) week 16 and ( b ) week 52, and with or without prior IRIC to STCs at ( c ) week 16 and ( d ) week 52. a Missing values at week 16 were imputed by the worst observation carried forward method if due to rescue treatment, adverse events, or lack of efficacy and by multiple imputations if due to other reasons. IRIC, inadequate response, intolerance, and/or contraindication; LS, least squares; NI, number imputed; PESQ-C, Pediatric Eosinophilic Esophagitis Sign/Symptom Questionnaire—caregiver version; STC, swallowed topical corticosteroid.
非 KM Figure